Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC
Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.
EP: 1.Overview of ccRCC and Introduction to the CheckMate 9ER Trial
EP: 2.A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial
EP: 3.CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective
Now Viewing
EP: 4.Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC
EP: 5.A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions
EP: 6.Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC
EP: 7.Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma
Related Videos
